The post-hoc analysis of the ENV-IPF-101 study utilized the Brainomix 360 e-Lung platform to evaluate patient outcomes beyond traditional forced vital capacity measurements. By quantifying radiographic features in high-resolution CT scans, researchers identified measurable reductions in interstitial lung disease burden and fibrosis, alongside increases in total lung capacity. These findings suggest that objective, AI-derived imaging biomarkers can capture subtle biological changes that conventional clinical endpoints might overlook.

Dr. Lisa Lancaster of Endeavor BioMedicines noted that the technology’s capacity to detect statistically significant efficacy within a small cohort and short timeframe serves as a de-risking tool for drug development. Following these results, the two companies have committed to further collaboration, aiming to integrate quantitative imaging into future clinical trials for taladegib. Beyond this specific study, Brainomix is showcasing additional research at the ERS Congress, highlighting the role of automated CT quantification in risk stratification and the assessment of disease progression in pulmonary medicine.